Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
Retrieved on:
Monday, March 11, 2024
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D.
Key Points:
- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D.
- to the company’s board of directors.
- “Maha joins our Board at a pivotal moment for Alto, as we continue on our path and fulfill our ambition of redefining psychiatry with our precision pipeline in areas of persistent medical need,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto.
- “Throughout her distinguished career, Maha has been dedicated to advancing patient care through more personalized approaches to treatment.